Noticias y eventos de PTC Therapeutics Inc (PTCT)

$70.090

-1.682 (-2.40%)Al cierre

Noticias de PTCT

8.508-13NASDAQ.COM

PTC Therapeutics Acquires ST-920 Gene Therapy for Fabry Disease

9.507-30seekingalpha

PTC Therapeutics Q2 Earnings Exceed Expectations

5.007-23PRnewswire

Hamilton Lane Appoints New Independent Director

9.507-16PRnewswire

PTC Therapeutics to Host Q2 2026 Earnings Call

5.007-14Fool

PTC Therapeutics Executive Stock Transaction Overview

5.007-14NASDAQ.COM

Analysis of Insider Stock Transaction at PTC Therapeutics

8.507-10NASDAQ.COM

Biotech Sector Shows Significant Recovery

5.006-17PRnewswire

PTC Therapeutics Approves Employee Stock Options

5.006-17Newsfilter

PTC Therapeutics Grants Stock Options to New Employees

8.506-16seekingalpha

PTC Therapeutics Prices $500M Convertible Notes Offering

Ver más noticias

Eventos de PTCT

8/24 08:30

PTC Therapeutics to Present Sephience Data at 2026 SSIEM Annual Symposium

PTC Therapeutics announced that multiple sephience scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28. The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine, significant diet liberalization and sustained metabolic control for the full spectrum of individuals living with phenylketonuria including those with classical PKU. In addition, Sephience studies continue to show a consistent and favorable safety profile. "The SSIEM presentations further demonstrate the broad clinical benefits of Sephience across the full spectrum of individuals living with PKU," said Matthew Klein, M.D., Chief Executive Officer. "In addition, new data to be presented at the PTC symposium show treatment with Sephience led to a large number of responsive participants achieving normalization of blood Phe levels in a rapid timeframe, including those with classical or non-BH4-responsive PKU. These impressive data support the potential benefits Sephience can deliver for individuals affected by PKU."

6/15 07:31

PTC Therapeutics Plans to Offer $500M Convertible Senior Notes

PTC Therapeutics announced that it intends to offer $500M aggregate principal amount of Convertible Senior Notes due 2031 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

6/4 14:20

FDA Pledges to Prevent Political Interference in Meeting with Rare Disease Nonprofits

Executives from 15 rare disease-focused nonprofits met on Wednesday with acting FDA Commissioner Kyle Diamantas and senior staff. In the meeting, Diamantas pledged to prevent political interference, Endpoint News' Zachary Brennan reports. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks include Replimune (REPL), Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).

6/2 09:50

FDA Issues Draft Guidance for Gene Therapies

The U.S. Food and Drug Administration said it has issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and regulatory knowledge. When finalized, the guidance will outline how sponsors can use publicly available information and established platform knowledge, including chemistry, manufacturing and controls data, nonclinical study results and clinical information, to streamline regulatory submissions for human gene therapy products that use genome editing in human somatic cells. "Today's action reflects the FDA's commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options," said Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research. "By providing information on how companies may build on what is already known we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on.Ultimately, this is about making sure that the promise of gene therapy reaches the patients who need it most, as quickly and safely as possible." This draft guidance supports the development of a wide range of cell and gene therapy products, including those that use genome editing, and is part of a broader set of complementary FDA actions in this area. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks include Replimune (REPL), Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).

5/12 16:20

Major Averages Finish Mixed as Semiconductor Stocks Pull Back

The major averages had a mixed finish as semiconductor stocks pulled back following a massive multi-week run. AI-driven enthusiasm pushed the S&P 500 and Nasdaq to fresh records yesterday, but investors are now confronting a harder macro backdrop than previously anticipated. Meanwhile, crude is back above $100 as hopes for a durable U.S.-Iran ceasefire continue to deteriorate, with President Trump describing negotiations as being "on life support." Of note, the Iranian Fars news service reportedly said that Iran will not join the next round of U.S. talks without five preconditions being met.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:eBay'sboard rejected GameStop'sUnder Armourreported mostly in-line Q4 results andActivist investor Nelson Peltz's Trian Fund Management is seeking investor backing for a bid to take Wendy'sprivate,BuzzFeedannounced a proposed majority investment byFDA Commissioner Marty Makary has, according to multiple media reports citing administration officials2. WALL STREET CALLS:Lowe'sto Buy at CitiAutodeskat Buy from Neutral at BofARothschildToaston risk from DoorDashU.S. rolloutZoomInfoto Underweight at Piper Sandler and to Neutral-equivalent ratings and several other firmsWall Streetof drone-maker Aevexafter its recent IPO3. AROUND THE WEB:Microsofthas already earned back more than double the capital it invested in OpenAI in terms of new revenue from services related to OpenAI, The Information reportsGoogleand Elon Musk's SpaceX are in talks for a rocket launch deal amid efforts to put orbital data centers in space, WSJ saysAlphabet'sYouTube is looking to connect creators with sponsors to secure funding for shows before they launch, NY Times reportsSoftBankis partnering with South Korea's Cosmos Lab and DeltaX to mass produce next-gen data center batteries in Sakai, Japan at a scale of 1 GWh/year from FY27, Bloomberg reportsBoeing'ssuccess hinges on its successor to the 737, Bloomberg says4. MOVERS:Zebra Technologiesrose after providing areport for Q1SI-Bonewas higher after also providing areport for Q1Gitlabfell after announcing aZoomInfowas lower afterand reiterating its FY26 outlookGoProdeclined after reportingand withdrawing its FY26 guidance5. EARNINGS/GUIDANCE:Sea LimitedreportedBayerprovided areport for Q1Qnity Electronicsalso provided areport for Q1Tencent Musicreported ain Q1 earningsHims & Hers Healthprovidedbut raised its FY26 revenue guidanceINDEXES:The Dow rose 56.09, or 0.11%, to 49,760.56, the Nasdaq lost 185.92, or 0.71%, to 26,088.20, and the S&P 500 declined 11.88, or 0.16%, to 7,400.96.

Ver más eventos

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.